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Abstract
Background Elevated intact parathyroid hormone (iPTH)
levels can contribute to morbidity and mortality in children
with chronic kidney disease (CKD). We evaluated the phar-
macokinetics, efficacy, and safety of oral paricalcitol in reduc-
ing iPTH levels in children with stages 3–5 CKD.
Methods Children aged 10–16 years with stages 3–5 CKD
were enrolled in two phase 3 studies. The stage 3/4 CKD
study characterized paricalcitol pharmacokinetics and com-
pared the efficacy and safety of paricalcitol with placebo
followed by an open-label period. The stage 5 CKD study
evaluated the efficacy and safety of paricalcitol (no compara-
tor) in children with stage 5 CKD undergoing dialysis.
Results In the stage 3/4 CKD study, mean peak plasma con-
centration and area under the time curve from zero to infinity
were 0.13 ng/mL and 2.87 ng•h/((or ng×h/))mL, respectively,
for 12 children who received 3 μg paricalcitol. Thirty-six chil-
dren were randomized to paricalcitol or placebo; 27.8% of the
paricalcitol group achieved two consecutive iPTH reductions
of ≥30% from baseline versus none of the placebo group (P =
0.045). Adverse events were higher in children who received
placebo than in those administered paricalcitol during the
double-blind treatment (88.9 vs. 38.9%; P = 0.005). In the
stage 5 CKD study, eight children (61.5%) had two consecu-
tive iPTH reductions of ≥30% from baseline, and five (38.5%)
had two consecutive iPTH values of between 150 and 300 pg/
mL. Clinically meaningful hypercalcemia occurred in 21% of
children.
Conclusions Oral paricalcitol in children aged 10–16 years
with stages 3–5 CKD reduced iPTH levels and the treatment
was well tolerated. Results support an initiating dose of 1 μg
paricalcitol 3 times weekly in children aged 10–16 years.
Keywords Secondary hyperparathyroidism . Paricalcitol .
Chronic kidneydisease–mineral andbonedisorder . Pediatric .
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Introduction
Chronic kidney disease-mineral and bone disorder (CKD-
MBD) is a common complication of progressive CKD [1].
Children and adults with stages 3–5 CKD frequently develop
secondary hyperparathyroidism (SHPT) with an elevated in-
tact parathyroid hormone (iPTH) level due to hypocalcemia,
hyperphosphatemia, and 1,25-dihydroxycholecalciferol
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deficiency [2–8]. SHPT may contribute to bone disorders,
vascular calcification, cardiovascular disease, and increased
mortality [2, 6, 9–13]. Unlike in adults, CKD-MBD in chil-
dren often results in growth retardation [14]. Serum levels of
iPTH are commonly used as a noninvasive measure of CKD-
MBD [15, 16].
The safety and efficacy of intermittent intravenous dosing
of paricalcitol as therapy for SHPT in children with CKD
undergoing dialysis have been previously demonstrated [17].
Children receiving hemodialysis treated with intravenous
paricalcitol had a statistically significant decrease in iPTH
levels from baseline compared with their counterparts receiv-
ing placebo (164 pg/mL decrease vs. 238 pg/mL increase,
respectively; P = 0.03) [17]. Several studies in adults with
stages 3 and 4 CKD and SHPT have demonstrated that intra-
venous paricalcitol efficacy in reducing iPTH is comparable
with that of calcitriol, but with a reduced likelihood of serum
calcium and phosphorus elevation [18, 19]. A retrospective
study reported similar results in children with SHPT undergo-
ing dialysis who were treated with intravenous paricalcitol
[20].
We report here the results of two prospective, phase 3 clin-
ical trials that were conducted to evaluate the pharmacokinet-
ics, efficacy, and safety of oral paricalcitol in reducing iPTH
levels in children with stages 3–5 CKD. These studies were
part of a postmarketing requirement from the U.S. Food and
Drug Administration to evaluate paricalcitol in the manage-
ment of CKD in pediatric patient populations. Using dosages
derived from an initial pharmacokinetic portion, the stage 3/4
CKD study further examined paricalcitol efficacy and safety
in children. The stage 5 CKD study evaluated the efficacy and
safety of paricalcitol capsules for the treatment of SHPT in
children with stage 5 CKD undergoing hemodialysis or peri-
toneal dialysis.
Methods
Stage 3/4 CKD study
Study design
The stage 3/4 CKD study (NCT01020487) was conducted in
two parts. Part 1 was an open-label, nonfasting, multicenter
study to evaluate the pharmacokinetics of paricalcitol in 10- to
16-year-old children with stage 3 or 4 CKD, conducted at
investigative sites within the USA. Blood samples for the
determination of paricalcitol serum concentrations were
drawn at 1, 2, 4, 6, 8, 12, 24, 36, and 48 hours following
paricalcitol dosing. In Part 2, conducted at investigative sites
within the USA (including Puerto Rico), Spain, Germany,
Portugal, the UK, and Singapore, the safety and efficacy of
oral paricalcitol for decreasing elevated serum iPTH levels in
10- to 16-year-old children with stage 3 or 4 CKD were com-
pared with placebo. The duration of treatment was a minimum
of 24 weeks. Part 2 included two treatment periods. The first
was a 12-week, randomized, double-blind, placebo-controlled
multicenter study in which children were randomized 1:1 to
receive paricalcitol capsules or placebo. In the second treat-
ment period, childrenwho completed the first treatment period
received open-label paricalcitol for at least 12 weeks. In Part 2,
children received the study drug for a minimum of 24 weeks
in total; children continued into a follow-up phase until all
enrolled children had completed 24 weeks on study drug. A
schedule of visits is provided in Electronic Supplementary
Material (ESM) 1A.
Study patients
Children (male and female; including kidney transplant recip-
ients in Part 2) were eligible for inclusion if they were 10–
16 years of age and had stage 3 or 4 CKD at screening {esti-
mated glomerular filtration rate (eGFR) 15–59 mL/min/
1.73 m2 (calculated using the Schwartz formula based on
GFR, height, and cystatin C levels) [21]}. For entry into the
treatment phase, children must have had all of the following:
iPTH ≥75 pg/mL (stage 3) or ≥110 pg/mL (stage 4), corrected
serum calcium ≥8.4 mg/dL (2.10 mmol/L) to ≤10.2 mg/dL
(2.55 mmol/L), serum phosphorus ≥2.5 mg/dL (0.81 mmol/
L) to ≤5.8 mg/dL (1.87 mmol/L), and 25-hydroxyvitamin D
level ≥30 ng/mL (for Part 2 only). Serum calcium was
corrected for albumin [2].
For Part 2 of the study, children with a history of solid
organ transplant at ≥12 months before entry into the
paricalcitol treatment phase were eligible but were required
to have a stable, therapeutic calcineurin inhibitor drug level,
defined as having ≥2 stable levels per investigator judgment,
before enrollment.
Children taking phosphate binders were required to have
been taking a stable dose (consistent type and regimen) per
investigator judgment, for a minimum of 4 weeks before
screening. Children receiving growth hormone were required
to have been receiving it for >3 months before screening and
were expected to continue to receive a stable dose throughout
the treatment phase.
Children with stage 3 or 4 CKD were excluded from the
study if they met any of the following criteria: history of a
solid organ transplant (in Part 1 only); bone marrow transplant
recipient on immunosuppressant therapy; acute kidney injury
within 12 weeks of screening; symptomatic or clinically sig-
nificant hypocalcemia requiring active vitamin D therapy
within 6 months of screening; active kidney stones within
6 months of screening; treatment with maintenance calcitonin,
bisphosphonates, cinacalcet, or glucocorticoids in an equiva-
lent dose of >5 mg prednisone daily, or other drugs known to
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affect calcium or bone metabolism within 4 weeks of therapy
initiation; use of phosphate supplements.
Institutional Review Board approval was obtained at all
participating sites before enrollment of any patients, and all
participants and/or parents or legal guardians provided signed
consent forms before screening.
Treatment
In Part 1 of the stage 3/4 CKD study, children received a single
3 μg oral dose of paricalcitol and were then assessed for in-
tensive pharmacokinetics for 48 h. In Part 2 of the stage 3/4
CKD study, children were randomly assigned to receive
double-blind paricalcitol (initial dose 1 μg) or matching pla-
cebo three times per week (TIW) for 12 weeks; children who
completed the 12-week double-blind period continued to the
12-week open-label period, for a total of 24 weeks. Some
children in Part 2 of the stage 3/4 CKD study continued
open-label therapy beyond 12 weeks during an extension of
the study period. Paricalcitol starting doses were adjusted to
iPTH, not to exceed 16 μg paricalcitol TIW. Beginning at
week 4, the initial paricalcitol dose could be increased in in-
crements of 1 μg every 4 weeks based on safety observations
and blood chemistry evaluations of iPTH, calcium, and phos-
phorus levels (see ESM 2 and 3 for dosing protocol). In gen-
eral, the target iPTH range was 35–70 pg/mL for children with
stage 3 CKD and 70–110 pg/mL for children with stage 4
CKD (ESM 3).
Study assessments
Pharmacokinetic parameters evaluated in Part 1 of the stage 3/
4 CKD study included maximum observed plasma concentra-
tion (Cmax), time to Cmax (peak time; tmax), terminal phase
elimination half-life (t1/2), and area under the plasma concen-
tration–time curve (AUC0–∞).
The primary efficacy endpoint of the stage 3/4 CKD study
was the proportion of children who achieved two consecutive
≥30% reductions from baseline in iPTH levels during the 12-
week double-blind portion of the study. Secondary efficacy
endpoints included the proportion of children who attained
final iPTH, calcium, and phosphorus levels within the
Kidney Disease Outcomes Quality Initiative (KDOQI) target
ranges by CKD stage: final iPTH (stage 3: 35–69 pg/mL;
stage 4: 70–110 pg/mL), calcium (age 6–12 years: 9.4–
10.2 mg/dL [2.35–2.55 mmol/L]; age 13–20 years: 8.8–
10.2 mg/dL [2.20–2.55 mmol/L]), and phosphorus (age 6–
12 years: 3.6–5.8 mg/dL [1.16–1.87 mmol/L]; age 13–20
years: 2.3–4.5 mg/dL [0.74–1.45 mmol/L]) levels.
Additional assessments included changes in eGFR, creati-
nine, calcium, and phosphorus from baseline. Adverse events
(AEs), changes from baseline in blood chemistry, hematology,
urinary laboratory analyses, vital signs, and physical
examinations were evaluated. Clinically meaningful hypercal-
cemia (2 consecutive corrected serum calcium values
>2.55 mmol/L [10.2 mg/dL]) was also assessed and was a
criterion for study discontinuation.
Statistical analyses
The Fisher exact test on the intent-to-treat populationwas used
to evaluate the primary efficacy endpoint for the stage 3/4
CKD study (proportion of children who achieved 2 consecu-
tive ≥30% reductions from baseline in iPTH levels during the
12-week double-blind period). A Cochran–Mantel–Haenszel
test was used to evaluate secondary endpoints, adjusting for
stage of CKD on the intent-to-treat population. Descriptive
statistics were recorded for the open-label period of Part 2 of
the stage 3/4 CKD study and for the safety assessment.
Stage 5 CKD study
Study design
The efficacy and safety of oral paricalcitol in 10- to 16-year-
old children with stage 5 CKD receiving peritoneal dialysis or
hemodia lys i s were eva lua ted in a second t r i a l
(NCT01382212), conducted at investigative sites within the
USA and Europe. Children received open-label paricalcitol
for 12 weeks. Because of the potential health risk associated
with 12 weeks of uncontrolled SHPT in children with stage 5
CKD, no placebo control group was included in the study. A
schedule of visits is provided in ESM 1B. Optional study site
visits at treatment weeks 6 and 10 were conducted at the dis-
cretion of the investigator to ensure safety and/or to make dose
adjustments.
Study patients
Children (male and female) aged 10–16 years with stage 5
CKD who were receiving peritoneal dialysis or hemodialysis
for ≥3 months before screening were eligible for the study. To
meet eligibility criteria, children were also required to be cur-
rently diagnosed with and/or receiving treatment for SHPT. If
taking phosphate binders, the patient was required to be on a
stable dose (consistent type and regimen) per investigator
judgment for ≥2 weeks before the start of screening.
Children receiving growth hormone were required to be
taking the hormone for >3 months before screening and were
expected to continue receiving a stable dose throughout the
study. Children receiving vitamin D receptor (VDR) activators
were required to meet inclusion and exclusion criteria before
completing a 2- to 12-week washout period. VDR activator-
naive children and children receiving VDR activators were
required to meet all specified laboratory values in the inclu-
sion and exclusion criteria before entering the dosing periods,
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namely, a corrected serum calcium level [2]; a phosphorus
value of ≤6.5 mg/dL (2.1 mmol/L); an iPTH level of
>300 pg/mL (31.6 pmol/L) and ≤2000 pg/mL (210.6 pmol/L).
Exclusion criteria for the stage 5 CKD study included the
following: anticipated living donor kidney transplant within
3 months of treatment; kidney transplant recipient currently
receiving full immunosuppressant therapy (full immunosup-
pressive doses of ≥2 immunosuppressant medications); antic-
ipated dialysis discontinuation within 4 months of screening;
parathyroidectomy within 12 weeks of screening; history of
gastrointestinal disease, active kidney stones, or clinically sig-
nificant hypocalcemia; concomitant treatment with calcitonin,
bisphosphonates, glucocorticoids, cinacalcet, prescription-
based phosphate supplements, or other drugs known to affect
calcium or bone metabolism.
Institutional Review Board approval was obtained at all
participating sites before enrollment of any patients, and all
participants and/or parents or legal guardians provided signed
consent forms before screening.
Treatment
Children in the stage 5 CKD study received paricalcitol cap-
sules TIW (not on consecutive days) for 12 weeks. The
starting dose was calculated using the following formula:
iPTH (in pg/mL)/120 = μg paricalcitol (rounded down to the
nearest whole number), where the iPTH value was that from
the last visit before study day 1. The starting dose was limited
to ≤16 μg TIW. The dose was adjusted to maintain an iPTH
level of 150–300 pg/mL (15.8–31.6 pmol/L) without exceed-
ing 16 μg TIW, based on iPTH, phosphorus, and calcium
results obtained during office visits (KDOQI ranges used as
target; ESM 3). Dose decreases were permitted at any time
(TIW increments 2 μg). Beginning at week 4, dose increases
related to iPTH levels were permitted in 4-week increments,
with 1 μg TIW adjustments.
Study assessments
Although the stage 5 CKD study did not include formal effi-
cacy endpoints, iPTH levels were recorded for the purposes of
dose adjustments. The proportion of children who achieved
two consecutive ≥30% reductions from baseline in iPTH
levels and the proportion of children who achieved two con-
secutive iPTH levels between 150 and 300 pg/mL during the
12-week study period were assessed. AEs, changes in baseline
blood chemistry, hematology, urinary laboratory analyses,
vital signs, and physical examinations were evaluated.
Clinically meaningful hypercalcemia (2 consecutive corrected
serum calcium values of >2.55 mmol/L [10.2 mg/dL]) was
also assessed.
Statistical analyses
The stage 5 CKD study did not include a comparator arm and,
therefore, no statistical analyses were performed. Descriptive
statistics were recorded for the proportion of children who
achieved two consecutive ≥30% reductions from baseline in
iPTH levels during the 12-week study period, the proportion
of children who achieved two consecutive iPTH levels be-
tween 150 and 300 pg/mL, and the safety assessment.
Results
Stage 3/4 CKD study
Study patients
A total of 48 children were enrolled in the stage 3/4 CKD
study (Part 1: n = 12; Part 2: n = 36). A summary of children
enrolled at each investigative site is provided in ESM 4. All 12
children enrolled in Part 1 completed the pharmacokinetic
study. Of the 36 children enrolled in Part 2, 80.6% (29/36)
completed the double-blind phase and initiated the open-label
phase, and 66.7% (24/36) completed the entire study
(≥24 weeks of study drug treatment). Figure 1a provides a
summary of the patient disposition for the stage 3/4 CKD
study.
Demographics and baseline characteristics of children en-
rolled in Part 2 of the stage 3/4 CKD study are provided in
Table 1. The majority of children were male and white. No
statistically significant differences were observed in baseline
clinical characteristics (sex, age, weight, race, and ethnicity)
between children enrolled in the placebo and paricalcitol arms
of Part 2. Demographics of the children enrolled in Part 1 were
similar to those enrolled in Part 2 (ESM 5). Baseline vital
signs and laboratory values for the intent-to-treat populations
from Part 2 are summarized in Table 1. No statistically signif-
icant differences were observed in the baseline vital signs or
laboratory values between the placebo and paricalcitol groups.
Pharmacokinetics
Oral paricalcitol was quickly absorbed and reached Cmax in
plasma at approximately 4 h (Fig. 2). The pharmacokinetics of
oral paricalcitol following a 3 μg dose were similar between
children with stages 3 and 4 CKD (Fig. 2; Table 2).
Efficacy and safety
During the double-blind period of the stage 3/4 CKD study,
five of the 18 children (27.8%) in the paricalcitol group
achieved the primary outcome of two consecutive reductions
of ≥30% from baseline in iPTH levels, compared with no
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children from the placebo group. The between-group differ-
ence of 27.8% was statistically significant (95% confidence
interval [CI] 7.5–52.8%; P = 0.045). The paricalcitol treat-
ment group also experienced greater overall iPTH reduction
from baseline; the mean between-group change in iPTH from
baseline to final assessment was −72.4 pg/mL (95% CI
−108.05 to −36.75 pg/mL; P < 0.001). At week 12, the mean
(standard error) change from baseline in iPTH was −17.1
(19.2) for the paricalcitol group compared with +71.5 (17.7)
for the placebo group. Children with stage 3/4 CKD treated
with paricalcitol achieved the primary outcome in similar pro-
portions (30 [3/10] and 25% [2/8], respectively); differences
in the proportions of children who achieved the primary out-
come between paricalcitol and placebo groups were not
statistically significant when analyzed by individual CKD
stage (stage 3 P = 0.090; stage 4 P = 0.467).
The proportion of children with stage 3/4 CKD achieving
calcium and phosphorus levels within the KDOQI range at the
final study visit was high and similar in the paricalcitol and
placebo arms of the study (Fig. 3). Compared with placebo, a
higher proportion of the total paricalcitol-treated population
achieved final iPTH levels within the KDOQI range (33.3
[6/18] vs. 11.1% [2/18]), but this difference was not statisti-
cally significant (P = 0.128).
The efficacy of paricalcitol in children with stage 3/4 CKD
in the open-label period was consistent with that of children in
the paricalcitol treatment group from the double-blind period.
Overall, of the 29 children for whom data were available, 12
a
b
Part 1 Part 2
Fig 1 Disposition of children. CONSORT flow diagrams for the stage 3/4 chronic kidney disease (CKD) study (a) and the stage 5 CKD study (b).
*Reasons were not mutually exclusive, †Dose reduction to <1 μg three times per week
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(41.4%) achieved two consecutive reductions of ≥30% from
baseline in iPTH levels, and eight (27.6%), 25 (86.2%), and
16 (55.2%) achieved final iPTH, calcium, and phosphorus
levels within KDOQI target ranges, respectively. During the
open-label period, iPTH levels decreased from baseline at week
16 (−34.4 pg/mL; 95% CI −64.9 to −3.8 pg/mL) and week 20
(−27.0 pg/mL; 95% CI −66.0 to 12.0 pg/mL), but increased by
week 24 (10.1 pg/mL; 95% CI −57.4 to 77.6 pg/mL).
Changes in laboratory measures, including eGFR, creati-
nine, calcium, and phosphorus, over the 12-week double-
blind period are summarized in Fig. 4. There were no statisti-
cally significant differences for any of the laboratory
Table 1 Demographics and
baseline Characteristic Stage 3/4 CKD Part 2 Stage 5 CKD
Treatment group Total study











Female 5 (27.8) 6 (33.3) 11 (30.6) 1.000 8 (61.5)
Male 13 (72.2) 12 (66.7) 25 (69.4) 5 (38.5)
Age (years) 13.3 ± 1.8 13.9 ± 1.8 13.6 ± 1.8 0.356 14.5 ± 1.8
Weight (kg) 48.2 ± 12.3 46.7 ± 10.2 47.4 ± 11.2 0.682 49.0 ± 19.7
Kidney transplant
recipient
8 (75.0) 1 (7.7)
Race
White 17 (94.4) 14 (77.8) 31 (86.1) 0.229 8 (61.5)
Black 0 0 0 2 (15.4)
Asian 0 3 (16.7) 3 (8.3) 1 (7.7)
American
Indian/Alaska native
0 0 0 1 (7.7)
Other 1 (5.6) 1 (5.6) 2 (5.6) 0
Multirace 0 0 0 1 (7.7)b
Ethnicity
Hispanic or Latino 5 (27.8) 4 (22.2) 9 (25.0) 1.000 6 (46.2)
No ethnicity 13 (72.2) 14 (77.8) 27 (75.0) 7 (53.8)
Baseline vital signs and laboratory values
Systolic BP
(mmHg)
117.06 ± 13.0 118.50 ± 14.9 117.78 ± 13.8 0.759 119.08 ± 18.9
Diastolic BP
(mmHg)
67.00 ± 10.8 65.61 ± 10.9 66.31 ± 10.7 0.702 68.38 ± 14.5
Albumin (g/dL) 4.66 ± 0.37 4.52 ± 0.42 4.59 ± 0.40 0.280 4.07 ± 0.37
Serum creatinine
(mg/dL)
2.33 ± 0.77 2.36 ± 0.96 2.34 ± 0.86 0.916 7.48 ± 3.15
Corrected serum
calcium (mg/dL)a
9.86 ± 0.42 9.70 ± 0.35 9.78 ± 0.39 0.214 9.24 ± 0.68
Serum phosphorus
(mg/dL)
4.44 ± 0.83 4.52 ± 0.56 4.48 ± 0.70 0.731 4.66 ± 1.13
iPTH (pg/mL) 155.44 ± 97.26 144.28 ± 64.86 149.86 ± 81.67 0.688 883.62 ± 373.81
25-Hydroxyvitamin
D (ng/dL)
40.78 ± 7.90 52.17 ± 50.26 46.47 ± 35.93 0.349 18.62 ± 10.81
Data in table are presented as the mean ± standard deviation (SD) or as a number with the percentage in paren-
theses, as appropriate
Baseline vital signs and laboratory values were not collected for children participating in Part 1 of the stage 3/4
CKD study
BP, Blood pressure; CKD, chronic kidney disease; iPTH, intact parathyroid hormone
a Corrected to an albumin level of 4.0 g/dL
b Identified as black and white
1226 Pediatr Nephrol (2017) 32:1221–1232
assessments between the paricalcitol and placebo groups at
any of the time points or overall.
A summary of AEs is provided in Table 3. Treatment-
emergent AEs were reported in two of the 12 children (16.7%)
in Part 1, but none were severe or serious. During the double-
blind period of Part 2, AEs were observed in a significantly
higher proportion of children in the placebo group than in the
paricalcitol group (16/18 vs. 7/18; P = 0.005). Two children in
the placebo group experienced a seriousAE comparedwith none
in the paricalcitol group. The most common AEs were viral
infection (16.7%), nasopharyngitis (11.1%), and hypercalcemia
(11.1%) in the placebo group, and rhinitis (16.7%) in the
paricalcitol group. One child in the paricalcitol group experi-
enced clinically meaningful hypercalcemia per study definition
(peak value 10.3 mg/dL). During the open-label period of Part 2,
AEs were reported in 18 of 29 children (62.1%), of which one
event was severe (3.4%) and two were serious (6.9%). Three
children experienced clinically meaningful hypercalcemia and
two experienced hyperphosphatemia.
Stage 5 CKD study
Study patients
A summary of study enrollment at investigative sites is provided
in ESM 4. Of the 13 children enrolled in the stage 5 CKD study,
all received one or more doses of paricalcitol and eleven (84.6%)
completed the study. One child discontinued after consent was
withdrawn, and one child discontinued because of a kidney
transplant. Patient disposition is summarized in Fig. 1b. A sum-
mary of demographics and baseline characteristics is provided in
Table 1 (last column); the majority of enrolled children were
female and white. Eight patients reported receiving hemodialysis
and seven received peritoneal dialysis, among whom two report-
ed receiving both hemodialysis and peritoneal dialysis. Baseline
vital signs and laboratory values for the intent-to-treat population
are summarized in Table 1 (last column).
Efficacy and safety
In the stage 5 CKD study, five of the 13 children (38.5%) had
two consecutive iPTH values between 150 and 300 pg/mL
and eight (61.5%) had two consecutive iPTH reductions of
≥30% from baseline. All 13 children were treated with
paricalcitol; 11 (84.6%) experienced an AE and two (15.4%)
experienced a serious AE (Table 3; last column). Overall, 23%
of children experienced clinically meaningful hypercalcemia
(defined as 2 consecutive serum calcium values of >10.5 mg/
dL) with paricalcitol during the study.
Table 2 Pharmacokinetic
parameters of paricalcitol in
plasma
Pharmacokinetic parameter Stage 3/4 chronic kidney disease (CKD) Part 1 Total study patients (n = 12)
Treatment group
Stage 3 CKD (n = 6) Stage 4 CKD (n = 6)
tmax (h)
a 4.0 (4–4) 4.0 (2–8) 4.0 (2–8)
Cmax (ng/mL) 0.12 ± 0.10 0.13 ± 0.05 0.10 ± 0.03
AUC0–∞ ng•h/((or ng×h/)) 2.6 ± 0.8 3.2 ± 1.0 2.9 ± 0.9
t1/2 (h)
b 13.3 ± 4.3 17.5 ± 5.9 14.5 ± 5.6
V/F (L) 27.8 ± 18.6 24.4 ± 5.9 26.2 ± 13.8
CL/F (L/h) 1.23 ± 0.4 1.02 ± 0.4 1.13 ± 0.4
Data in table are presented as the mean ± SD unless noted otherwise
AUC0–∞, Area under the curve; CL/F, oral clearance; Cmax, maximum observed plasma concentration; t1/2,
terminal phase elimination half-life; tmax, time to Cmax; V/F, apparent volume of distribution
aMedian (minimum–maximum)
bHarmonic mean and pseudo SD
Fig 2 Paricalcitol plasma concentration. Mean plasma concentration-
time profiles of paricalcitol. SD Standard deviation, CKD chronic kidney
disease




Fig 3 Proportion of children achieving final measures within Kidney Disease Outcomes Quality Initiative target ranges (intent-to-treat) for iPTH (a),
calcium (b), and phosphorus levels (c). iPTH Intact parathyroid hormone
a b
c d
Fig 4 Changes in laboratory values. a, b Changes in estimated glomerular filtration rate (eGFR; a) and creatinine levels (b) over time. c, d Changes in
calcium (c) and phosphorus (d) from baseline over time. BSA Body surface area
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iPTH, calcium, and phosphorus levels over the 12-week
double-blind period in patients with stage 5 CKD are shown
in Fig. 5. With the exception of the expected decrease in iPTH
with paricalcitol, there were minor changes in calcium and
phosphorus over the 12-week period.
Discussion
Although CKD differs in adults and children, the pathophysi-
ology of SHPT, which is characterized by elevated iPTH levels
and parathyroid gland hyperplasia, is an early and common
complication regardless of age group [2–8]. The occurrence
of elevated iPTH levels is the major contributor to the high-
turnover bone disease seen in both adults and children and to
the clinical symptoms of extraskeletal calcification, bone pain,
and fractures [1]. Unlike in adults, the complications of bone
disease in children with CKD also manifest clinically as growth
retardation and musculoskeletal deformities [14].
Clinical studies in adult patients with stage 3 or 4 CKD
have shown that paricalcitol capsules significantly reduce
iPTH levels, with no significant difference between
paricalcitol capsules and placebo in terms of incidences of
hypercalcemia, hyperphosphatemia, and elevated calcium–
phosphorus product [22]. However, limited clinical data are
available for the use of paricalcitol in children with SHPT
associated with CKD.
In our study, Cmax, AUC0–∞, tmax, and t1/2 values for
paricalcitol appeared to be similar in children with stage 3 or
4 CKD. The exposure (AUC) of paricalcitol in children with
stage 3 or 4 CKD was numerically higher than that observed
in adults with stage 3 or 4 CKD [22]. Based on prospectively
defined criteria for the selection of the paricalcitol dose for
Part 2 of the stage 3/4 CKD study, we selected a dose of
1 μg paricalcitol TIW as the initial dose in the efficacy and
safety portion of the study, and the results support an initiating
dose of 1 μg paricalcitol TIW in future paricalcitol studies in
children aged 10–16 years, as well as in clinical practice. The
population pharmacokinetic analysis shows that the pharma-
cokinetics of paricalcitol in pediatric patients with stage 5
CKD appeared to be similar to those observed in pediatric
patients with stage 3 or 4 CKD (data on file). These analyses
indicate that renal function does not impact paricalcitol expo-
sure in pediatric patients, which is also consistent with the
findings in adults [22].
Paricalcitol was effective in reducing iPTH levels in the
children with stage 3 or 4 CKD enrolled in our study, and
there was a statistically significantly greater proportion of chil-
dren who achieved two consecutive reductions of ≥30% from
baseline in iPTH levels with paricalcitol treatment compared
Table 3 Summary of treatment-emergent adverse events
Treatment-emergent AE Stage 3/4
CKD Part 1
Stage 3/4 chronic kdiney disease (CKD) Part 2 Stage 5
CKD
All treated Double-blind phase Open-label phase All treated
Treatment group Total study
patients (n = 36)
Treatment group Total study












arm (n = 13)
Paricalcitol
(n = 13)
Any AE 2 (16.7) 16* (88.9) 7* (38.9) 23 (63.9) 12 (75.0) 6 (46.2) 18 (62.1) 11 (84.6)
Any AE possibly related to
study druga
0 1 (5.6) 2 (11.1) 3 (8.3) 4 (25.0) 1 (7.7) 5 (17.2) 2 (15.4)
Any severe AEb 0 2 (11.1) 0 2 (5.6) 0 1 (7.7) 1 (3.4) 0
Any serious AE 0 2 (11.1) 0 2 (5.6) 1 (6.3) 1 (7.7) 2 (6.9) 2 (15.4)
Any AE leading to
discontinuation of study
drug
0 2 (11.1) 1 (5.6) 3 (8.3) 4 (25.0) 1 (7.7) 5 (17.2) 0
Any fatal AE 0 0 0 0 0 0 0 0
Deathsc 0 0 0 0 0 0 0 0
*Statistically significant difference between placebo and paricalcitol at P = 0.005 according to the Fisher exact test
Values in table are expressed as a number with the percentage in parenthesis
AE, Adverse event
a Investigator assessment
b Defined as an adverse event with maximum severity, regardless of organ affected
c Includes deaths that were not treatment emergent
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with placebo. Overall, there was a greater reduction in iPTH
levels from baseline to final assessment in the paricalcitol
treatment group than in the placebo arm. The fact that most
children enrolled in the study did not have severe SHPT and
had well-controlled mineral metabolism may explain the ob-
served moderate decrease in iPTH. The effect of paricalcitol
treatment was sustained in children with stage 3 or 4 CKD for
approximately 20weeks. The decrease in suppression of iPTH
observed at week 24 in the open-label study supports ongoing
monitoring of iPTH levels in children treated with paricalcitol.
Adjustment of paricalcitol dosage to maintain reductions in
iPTH levels should take into account concurrent calcium and
phosphorus levels.
In the stage 3/4 CKD study, there was no difference
between treatment groups in the proportion of children
who achieved final iPTH, calcium, or phosphorus levels
within KDOQI targets. Changes in laboratory values were
also similar between the paricalcitol and placebo groups.
The iPTH results suggest that a larger study population
may have yielded a significant difference in the achieve-
ment of KDOQI target range between groups. A high pro-
portion of children in the placebo group achieved calcium
and phosphorus levels within KDOQI ranges, suggesting
that a significant improvement with paricalcitol treatment
may be unlikely. Both eGFR and creatinine levels
remained stable throughout the course of the 12-week
double-blind portion of the stage 3/4 CKD study, suggest-
ing that renal function was not significantly affected by
paricalcitol treatment.
Consistent with previous studies, hypercalcemia events
with paricalcitol treatment were rare [17, 19, 23]. Overall,
paricalcitol was well tolerated in children with stages 3–5
CKD.Most AEs were mild, with few serious or severe events,
and no new clinically concerning safety signals were observed
in either study.
The results presented herein are consistent with those of
Greenbaum et al. [17] who demonstrated the efficacy of intra-
venous paricalcitol. Previous studies have demonstrated that
calcitriol and doxercalciferol exhibit efficacy in lowering PTH
levels and help to control bone turnover [24, 25]; however, it
has also been reported that intermittent high-dose calcitriol
may adversely affect linear bone growth [26]. Paricalcitol is
effective in reducing iPTH levels without typically elevating
the levels of calcium and phosphorus and may have an even
greater potential to control bone turnover while minimizing
the risk of adverse effects on linear bone growth. Future stud-





















































Fig 5 Changes in intact parathyroid hormone (iPTH; a), calcium (b), and phosphorus (c) over time in patients with stage 5 chronic kidney disease
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Both studies share the limitations inherent in trials of short
duration or limited number of patients that seek to determine
differences in outcome measurements and identify potential
safety concerns. Despite the limited number of patients, com-
pletion rates in the stage 3/4 CKD study (80.5% in the double-
blind phase) and stage 5 CKD study (84.6%) were high com-
pared with other studies of this type [17, 23]. A larger and
longer study may have allowed for detection of differences in
efficacy and safety between children with stage 3 and stage 4
CKD. It is also possible that larger studies of longer duration
would have increased the potential for observation of infre-
quent AEs. Inclusion of children with stage 3 CKD who were
vitamin D replete may have limited the potential to markedly
reduce iPTH levels in the study population. In children with
stage 3 CKD with adequate levels of calcifediol, active vita-
min D supplementation may not be necessary to manage sec-
ondary hyperparathyroidism [3].
In summary, data from these studies demonstrate that the
treatment of children aged 10–16 years with stages 3–5 CKD
with oral paricalcitol was effective in lowering iPTH levels
and was well tolerated over extended trial periods.
Additionally, the administration of paricalcitol capsules for
the treatment of SHPT in pediatric patients aged 10–16 years
with stage 3 or 4 CKD appears to be similar to that observed in
adult patients. These results support an initiating dose of 1 μg
paricalcitol TIW in future paricalcitol studies in children 10–
16 years of age with CKD, as well as in clinical practice.
Future studies will need to evaluate dosing, efficacy, and safe-
ty of oral paricalcitol in younger children with CKD.
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